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Abstract
Background: von Hippel-Lindau (VHL) disease is a rare hereditary tumor syndrome caused by VHL gene mutations
that is characterized by heterogeneous phenotypes such as benign/malignant tumors of the central nervous
system, retina, kidney, adrenal gland, and pancreas. The genotype-phenotype correlation has not been well
characterized in the Korean population so far. Therefore, this study aimed to evaluate the VHL mutation spectrum
and genotype-phenotype correlations in Korean VHL patients.
Methods: Thirteen unrelated subjects with VHL mutations were included. Direct sequencing and multiplex ligation-
dependent probe amplification were performed. Consequently, the clinical manifestations and family histories of
the subjects were evaluated.
Results: We identified 10 different VHL mutations. The c.160_161delAT frameshift mutation was novel. Missense
mutations clustered in 2 domains (α domain in exon 1; β domain in exon 3). The most frequently observed
mutation was c.208G > A (p.Glu70Lys). Milder phenotypes were observed in subjects with de novo mutations.
Age-specific risk for CNS hemangioblastoma was significantly higher in subjects carrying missense mutations within
the HIF-α binding site (P < 0.05).
Conclusions: This study provides insight into the genotype-phenotype correlation in that amino acid substitutions
in the HIF-α binding site may predispose patients to age-related risks of CNS hemangioblastoma.
Keywords: Genotype-phenotype correlation, Hypoxia-inducible factor 1, von Hippel-Lindau disease,
von Hippel-Lindau Tumor suppressor protein
Background
von Hippel-Lindau disease (VHL) (OMIM no.193300) is an
uncommon autosomal dominant cancer syndrome result-
ing from mutations in the VHL tumor suppressor gene.
The reported incidence of VHL is about 1 in 36,000–
53,000 births worldwide, with age-dependent high pene-
trance [1–3]. The VHL-related tumors include central
nervous system (CNS) hemangioblastomas (CHBs), retinal
hemangioblastomas (RHBs), pheochromocytomas (PCCs),
renal cell carcinomas (RCCs), endolymphatic sac tumors
(ESTs), epididymal cystadenomas, and broad ligament
cystadenomas. Additionally, VHL patients often exhibit
multiple cysts in various organs including the pancreas and
kidney [4].
VHL is located on chromosome 3p25.3, and it was first
identified in 1993 [5]. The encoded VHL protein (pVHL)
forms a complex with elongation factor C and B (elongin
C/B), which, along with cullin2 (CUL2) and RING finger
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protein (RBX1), constitutes the VCB-CR complex. When
stabilized, the VCB-CR complex successfully regulates
hypoxia-inducible factor α (HIF-α); the prolyl hydroxyl-
ated HIF-α directly binds to the β domain of pVHL, and
is consequently targeted for polyubiquitination and pro-
teasomal degradation [2]. When pVHL does not regulate
HIF-α, the stabilized HIF-α accumulates and stimulates
pro-angiogenic factors, such as vascular endothelial growth
factor (VEGF) and platelet-derived growth factor β
(PDGFB) accelerating tumorigenesis [6].
VHL is clinically classified into 4 phenotypic categories:
Type 1 does not include PCC; Type 2A includes PCC but
not RCC; Type 2B includes both PCC and RCC; and Type
2C is associated with PCC as the sole manifestation.
Genotype-phenotype correlation studies have provided
critical strategies for prophylactic surveillance and gen-
etic counseling of presymptomatic members in VHL
families [7, 8]. While the VHL genotype-phenotype cor-
relation has been investigated in Western countries, the
correlations in Korean populations have not yet been
well studied [4, 9, 10].
In this study, we investigated the VHL mutation




Thirteen unrelated patients with germline VHL muta-
tions who were diagnosed with VHL disease were evalu-
ated. Patient medical records such as MRI of the brain
and the whole spine with contrast, eye examinations,
and imaging scans of the abdomen were retrospectively
reviewed. In addition, patients were interviewed to ob-
tain information regarding their family history, through
which three-generation pedigree data was collected
(Fig. 1). The overall observation period ranged from
1988 to 2015. The average follow-up of the subjects was
11.0 years (range: 2–28 years). The study was approved
by the institutional review board of the Seoul National
University Hospital. Informed consent was obtained
from all participants or their parents.
Genetic analysis
Genomic DNA was extracted from peripheral blood
using the Gentra Puregene Blood kit (Gentra Systems,
Minneapolis, MN, USA), according to the manufac-
turer’s instructions. All coding exons and flanking in-
tronic regions were amplified by PCR using primers
specific for VHL exons 1–3. The amplified product was
Fig. 1 Pedigrees of VHL families (family 1, 3, 5, 9, 11, 12 and 13). Black symbols represent the affected subjects. Probands are marked with arrows.
A further family history assessment of family 4 was not available
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directly sequenced with an ABI PRISM 3730xl DNA
Analyzer (Applied Biosystems, Foster City, CA, USA)
using the BigDye Terminator v.3.1 Cycle Sequencing Kit
(Applied Biosystems).
For screening exon deletions and duplications, multiplex
ligation-dependent probe amplification (MLPA) P016-C1/
P16-C2 kits (MRC-Holland, Amsterdam, Netherlands)
were used. DNA denaturation, probe-target sequence
hybridization, probe ligation, and PCR amplification of
ligated probes were performed according to the manu-
facturer’s instructions. The products were loaded onto
ABI PRISM 3130xl DNA Analyzer (Applied Biosystems)
and analyzed by GeneMarker software version 1.51
(SoftGenetics, LLC, State College, PA, USA).
Statistics
The tumors in the 2 different VHL mutation groups
(inherited mutations vs. de novo mutations) were
compared using the Mann–Whitney U test. Kaplan–
Meier estimates with log-rank test were used to calculate
the age-related penetrance of VHL-associated tumors. P
values less than 0.05 were considered statistically signifi-
cant. Data was analyzed using SPSS version 21.0 soft-
ware (IBM-SPSS Inc, Chicago, IL, USA).
Results
Cases
Patient 1, a 49-year old male (Table 1), presented with
gait disturbance and vertigo. MRI evaluation revealed
hemangioblastoma at the right superior cerebellum. A
year after excising the mass, bilateral 2.2–4.0 cm tumors
were found in both kidneys. Eye examination revealed a
hemangioma-like lesion in the right eye. In addition, CT
of the abdomen revealed a pancreatic neuroendocrine
tumor (NET). Genetic testing showed that the patient
harbored a novel frameshift mutation, p.Met54Glyfs*77,
Table 1 Germline VHL mutation and its phenotypes in 13 VHL families
Family Sex FHx Exon Nucleotide change AA change VHL type CHB RHB RCC PCC PC KC Others Reference
1 M Proband 1 c.160_161delAT p.Met54Glyfs*77 1 49 64 51, B – 64, M – –
M Son 1 c.160_161delAT p.Met54Glyfs*77 1 – – – – 38, M 38, B + –
F Daughter 1 c.160_161delAT p.Met54Glyfs*77 1 35 – 35 – 35, M 35, B –
2 M – 1 c.208G > A p.Glu70Lys 1 25 – – – – – 14, 19
3 F Proband 1 c.208G > A p.Glu70Lys 1 – 46, B – – – – 14, 19
M Son 1 c.208G > A p.Glu70Lys – – – – – – – 14, 19
4 F Proband 1 c.208G > A p.Glu70Lys 1 – 20, B – – – – 14, 19
F Mother NA NA NA 1 – 20, B – – – –
5 M Proband 1 c.227_229delTCT p.Phe76del 1 12 – 19, B – 13, M – 4
M Brother NA NA NA 1 19 – 18, B – 23, M 19, B
F Sister IVS1 c.340 + 5G > C – – – – – – – +
Father NA NA NA 2B 27 – 44,B 44 44,M 44,B
6 M – 1 c.232A > G p.Asn78Asp 1 11 – – – 20, M 20 15
7 M – 1 c.233A > G p.Asn78Ser 1 14 14 – – 14, M 14, B 4
8 M – IVS2 c.464-1G > T 1 38 – – – 38, M 38 4
9 M Proband 3 c.499C > T p.Arg167Trp 2B 47 – 47 47 47, M 48 4
F Niece 3 c.499C > T p.Arg167Trp 1 14 26, B 32 – 26, M 32, B 4
10 F – 3 c.500G > A p.Arg167Gln 1 59 – – – 59, M 59, B 4
11 M Proband 3 c.500G > A p.Arg167Gln 1 36 41, B 48, B – – 48, B 4
M Son 3 c.500G > A p.Arg167Gln 1 15 – – – – – 4
12 F Proband 3 c.592delC p.Leu198Trpfs*4 2C – – – 24 21, M – 19
F Mother 3 c.592delC p.Leu198Trpfs*4 2C – – – 27 48, M – + 19
13 M Proband Exon2, 3 deletion 1 32 44 44, B – 41 – 4
M Son Exon2, 3 deletion – – – – – – – 4
M Brother Exon2, 3 deletion 1 29 52 43, B – 43, M 43, B 4
M Nephew NA NA NA 1 22 18 29, B – 18, M –
Abbreviations: CHB, CNS hemangioblastoma, RHB retinal hemangioblastoma, RCC renal cell carcinoma, PCC pheochromocytoma, PC pancreas lesion (pancreatic cyst
or pancreatic tumor), KC renal cyst, Other includes developmental venous anomaly or meningioma, B bilateral, M multiple, AA amino acid, FHx family history, NA
not tested
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in the VHL gene. One of his daughters and his son were
heterozygous for the same mutation. His 35 year-old
daughter had 3 types of VHL-related tumors: Cerebellar
hemangioblastoma, RCC in the right kidney lower pole,
and pancreatic NET which invaded the superior mesen-
teric artery and superior mesenteric vein. His son, who
was 38 years old, visited an emergency room presenting
with a generalized tonic-clonic seizure. On evaluation,
the brain MRI showed a well-defined mass in the left
parietal area, which was pathologically found to be a
meningioma.
Patient 2 was a 25-year-old male (Table 1) who re-
ported frequent headaches and dizziness. MRI of the
brain revealed a 0.9-cm nodular lesion at the medullo-
cervical junctional level. This patient underwent mid-
line suboccipital craniotomy. A heterozygous missense
mutation was identified in the VHL gene: p.Glu70Lys.
There was no family history. This patient regularly
visited the clinic, and no other VHL-related tumor
developed.
Patient 3 was a 46-year-old female who was the index
patient in family 3 (Table 1). She visited the clinic with a
3-month history of blurred eye vision in her left eye.
Examination revealed RHB in her left eye. VHL analysis
revealed the heterozygous missense mutation p.Glu70Lys.
Since her sister had suffered from RHB, the mutation was
considered to be passed down from her parents. Her son,
a 19-year-old male, inherited the same mutation, but no
VHL-related symptoms were present. He underwent sur-
veillance for VHL manifestations. RHB was the only VHL-
related phenotype in this family.
Patient 4 was a 20-year-old female (Fig. 1). Through
routine eye examination, multiple RHBs in both eyes
were found. We analyzed the VHL gene and found that
the patient was heterozygous for the p.Glu70Lys muta-
tion. Her mother had been treated for RHB but refused
to undergo genetic analysis. Further genetic testing and
family history assessment was unavailable for this family.
No other VHL-associated symptoms were observed in
patient 4 and her mother.
In family 5, two siblings (Table 1) underwent surgical
resection for CHB at the ages of 12 and 19. Abdominal
CT revealed RCCs in these siblings. The family history
revealed VHL manifestations in their father who died in
2013 and had RCC, PCC, and CHB (Table 1). The pro-
band (patient 5) harbored an in-frame deletion p.Phe76-
del affecting exon 1 in the VHL gene. This in-frame
deletion appeared to run in this family.
Patient 6 described nausea and vomiting at the age of
11. Imaging studies showed multiple enhancing soft tis-
sue masses on the cerebellar tonsil, cerebellar hemi-
sphere, and cervical spinal cord. CT of the abdomen
revealed pancreatic and renal cysts along with pancreatic
NET. VHL analysis revealed a heterozygous substitution
c.232A > G, which leads to the p.Asn78Asp mutation.
This patient had no family history.
Patient 7 was 14-year-old male who experienced fre-
quent abdominal distension and intermittent headaches.
At a routine health check-up, multiple pancreatic cystic
lesions and RHB in the temporal disc side of his left eye
were found. MRI of the brain showed a tiny well-
enhanced nodule at the cervicomedullary junction with
an adjacent prominent vascular structure. The features
of this patient’s presentation were indicative of VHL. Al-
though this patient had no family history, a heterozygous
missense VHL mutation, p.Asn78Ser, was identified in
patient 7.
Patient 8, a 38-year-old male, showed mild imbalance
with gait difficulty. MRI of the brain revealed a 3.5-cm
cystic mass in the cerebellum, which was pathologically
found to be hemangioblastoma. When this patient
underwent CT, which included the pancreas and kidney,
multiple pancreatic cysts and renal cysts were found. A
VHL c.464-1G > T splicing mutation was detected in pa-
tient 8 and there was no family history of VHL disease
in his family.
Patient 9 was a 47-year-old male (Table 1). He pre-
sented with dizziness and headache, which he had expe-
rienced for the 3 months prior to examination. After
systemic examination, multiple VHL related tumors
were revealed, including RCC, PCC, and CHB. VHL ana-
lysis detected a heterozygous missense mutation,
p.Arg167Trp. He had a family history of VHL-related tu-
mors, including CHB and RCC. His brother was diag-
nosed with CHB and his niece was diagnosed with CHB,
RHB and RCC. The same mutation was identified in his
niece.
Patient 10 (Table 1), a 59-year-old female, presented
with indigestion, anorexia, and nausea. This patient
underwent abdominal CT; multiple renal cysts, a hyper-
vascular mass in the pancreatic body, and a cystic mass
in the pancreatic head and tail were found. Pylorus pre-
serving pancreaticoduodenectomy was performed in this
patient. Two months after surgery, gait disturbance ap-
peared. MRI of the brain revealed multiple enhancing
masses in both cerebellums, which were pathologically
found to be hemangioblastoma. Based on suspicion of
VHL, we sequenced the VHL gene in this patient; a het-
erozygous missense VHL mutation, p.Arg167Gln, was
confirmed. None of her family members were affected.
Patient 11 (Table 1) was diagnosed with VHL at the
age of 36 years, while his son was diagnosed at the age
of 15 years. Patient 11 presented with nausea, vomiting,
and left-side weakness, developed within 2 days. MR
brain images revealed a hemangioblastoma-like cystic
mass in the cerebellum. He therefore underwent cerebel-
lar tumor resection. When he was under observation,
RHB and RCC were detected at the ages of 41 and
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48 years, respectively. Patient 11 and his son shared a
heterozygous missense mutation, p.Arg167Gln, in the
VHL gene. The mother and sisters of patient 11 were
also suspected to have VHL mutations, but their DNA
was not evaluated.
Patient 12 and her mother were diagnosed with
pheochromocytoma at the ages of 24 and 27 years,
respectively (Table 1). A frameshift mutation, p.
Leu198Trpfs*4, in the VHL gene was detected in these
2 subjects.
Patient 13, his brother, and his nephew were diagnosed
with VHL. RCC and CHB were passed from generation
to generation (Table 1). A large deletion spanning exons
2–3 in the VHL gene was detected in patient 13, his
brother, and his asymptomatic son.
Clinical characteristics of patients
A total of 13 unrelated probands (9 males and 4 fe-
males) were analyzed in our study (Table 1). Their
mean age at first manifestation was 31.5 ± 15.7 years.
CHB was the most common presenting phenotype
(n = 10, mean age at diagnosis 32.3 ± 16.7 years),
followed by pancreatic lesions (n = 9, mean age at
diagnosis 35.2 ± 19.2 years), renal cysts (n = 6, mean
age at diagnosis 37.8 ± 17.6 years), RHB (n = 6, mean
age at diagnosis 38.2 ± 18.4 years), RCC (n = 5, mean
age at diagnosis 41.8 ± 13.0 years), and PCC (n = 2, mean
age at diagnosis 35.5 ± 16.3 years). Excluding PCC, bilat-
eral or multiple lesions frequently occurred in VHL
related tumors: 80.0 % in CHB, 50.0 % in RHB, 80.0 % in
RCC, 88.9 % in pancreatic lesions, and 50.0 % in renal
cysts. Among the 13 patients who were carriers of VHL
mutations, 8 (61.5 %) had a family history of the disease
while the other 5 (38.5 %) had no VHL family history;
thus, the latter group was considered as having de novo
germline VHL mutations.
Mutation distribution in VHL disease
In our study, 10 different VHL germline mutations were
confirmed in 13 unrelated VHL patients (Table 1). Our
data showed that 61.5 % (8/13) of probands had mis-
sense mutations and 15.4 % (2/13) had frameshift muta-
tions. In-frame deletion, splicing mutation, and exon
deletion were found in each 7.7 % (1/13) of the pro-
bands. The novel mutation c.160_161delAT (p. Met54-
Glyfs*77) was identified.
Mutations were mainly concentrated in 2 domains, α
and β, while no mutation was found in the codons from
1 to 53 (Fig. 2).
Missense mutations (p.Arg167Trp and p.Arg167Gln)
in codon 167, in which VHL mutations frequently occur
throughout all ethnic groups, were also observed in
Korean population: p.Arg167Trp, in 1 proband (7.7 %)
and p.Arg167Gln, in 2 unrelated probands (15.4 %).
Interestingly, the most frequently observed mutation
was c.208G > A (p.Glu70Lys), which occurred in 3 unre-
lated probands (23.1 %).
Fig. 2 Distribution of germline mutations in VHL patients. Three exons are shown by boxes and α/β domains are indicated by colored boxes. The
horizontal bars indicate binding domains. A splice site mutation, c.464-1G > T is not shown in this figure
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Genotype-phenotype correlations
Three subjects carrying the c.208G > A (p.Glu70Lys)
mutation manifested only CHB or RHB; 1 patient had
only CHB and the other 2 patients manifested only
RHB. No other phenotype was observed in these 3
patients. Notably, RHB developed more frequently in
patients with c.208G > A mutation (2/3, 66.7 %) than in
patients with other mutations (4/10, 40.0 %).
Patients with de novo VHL germline mutation had sig-
nificantly lower number of tumors (mean 1.6 tumors)
than patients with a family history of the mutation
(mean 3.4 tumors) (P = 0.007, Fig. 3a). RCC was not
present in patients with de novo VHL mutations
(Table 1).
All of the pathogenic missense mutations were con-
centrated within either the HIF-α binding site (residues
65–117) or the elongin C binding site (residues 158–
170) (Fig. 2). With regard to the age-related penetrance,
patients carrying amino acid substitutions in HIF-α
binding site had a significantly higher risk for CHB
than patients carrying missense mutations in another
site (P = 0.025) (Fig. 3b). Interestingly, while the age-
related risk between the group of patients with an
overall missense mutation and other patients was not
significantly different (Fig. 3c), missense mutations es-
pecially occurring at the HIF-α binding site increased
the age-specific penetrance for CHB (Fig. 3d).
Our mutation profile did not represent the correlation
between type 2 VHL and missense mutations: PCC was
found in 2 subjects, who were carrying a missense
mutation c.499C > T (p.Arg167Trp) and a frameshift
mutation c.592delC (p.Leu198Trpfs*4). The c.592delC
mutation was predicted to interrupt the 198th codon in
VHL coding regions (codons 1–213).
We did not find any association between RCC and
truncating VHL mutations. The incidence of RCC was
not significantly higher in patients with truncating VHL
mutations than in those missense mutations (66.7 % vs.
33.3 %, P = 0.523). Furthermore, age-related RCC risk
between patients with truncating mutations and those
with missense mutations was not significantly different
(P = 0.455).
Discussion
This study describes the unique phenotypic traits and
mutation spectrum of VHL syndrome in 13 Korean
Fig. 3 Phenotypic traits of Korean VHL patients. a Number of VHL-related tumors in 2 groups of VHL patients (de novo mutation vs. familial mutation).
The patients are represented on the x-axis. b–d Age-related penetrance of CHB in VHL mutations. b HIF-α binding site vs. elongin C binding
site. c Missense mutations vs. other mutations. d Missense mutations within the HIF-α binding site vs. other mutations
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families. Our data showing that missense mutations were
all clustered in either HIF-α or elongin C binding sites
supports previous findings that these two binding sites
have a role in VHL protein function [2, 4, 11]. Previous
studies suggested that dysregulated HIF-α is the chief
causative factor of hemangioblastoma, a highly vascular
tumor [2, 4]. We speculate that missense mutations dis-
rupting HIF-α binding can increase the risk for early-age
onset of CHB. It has previously been reported that the
mean age at diagnosis for VHL-associated CHB is
32 years [12], while our data showed that CHB patients
harboring missense mutations in the HIF-α binding site
developed CHB at an early age (mean 16.7 years). The
HIF-α binding site mutations in our data include Asn78-
Ser, Asn78Asp, and Glu70Lys. All of the HIF-α binding
site missense mutations observed in this study were pre-
viously identified to reduce HIF-α degradation [13–15].
Asn78Ser disables binding as well as ubiquitination of
HIF-α, while it retains binding of elongin C, both in
vitro and in vivo [13]. The pVHL L1 loop mutant
Glu70Lys disrupts HIF-α binding activity and HIF-2a
degradation in vivo [14]. However, Arg167Gln is located
within the elongin C binding site, which only eliminates
the elongin C binding. The Arg167Gln mutant still has
remnant VHL–elongin BC complex and retains wild-
type levels of HIF1-α regulation [16]. Since HIF-α
dysregulation is a critical step in the development of
hemangiomas, disruption of functional pVHL that regu-
lates HIF-α can accelerate CHB progression. Inhibition
of HIF-α degradation may lead to overexpression of
hypoxia-inducible mRNAs such as VEGF, which pro-
motes tumor angiogenesis, especially in highly vascular-
ized tumors, including CHB [2]. Thus, patients
harboring HIF-α binding site missense mutations may
show accelerated onset of CHB, manifested by rapid rate
of tumor growth.
Interestingly, two patients with elongin C binding site
mutations also presented CHB onset at an early age (at
14 and at 15 years, respectively) (Table 1). These two pa-
tients were the niece and the son of the study subjects,
probands of family 9 and 11, respectively. The onset age
may be earlier in offspring of the probands than in the
probands themselves. A previous study suggested that
this is expected in families with VHL disease [17], sup-
porting our findings.
Our findings suggest that categorizing missense muta-
tions according to their effect on HIF-α regulation
enables strict follow-up of high-risk patients for early-
onset hemangioblastomas.
Our results show that 38.5 % (5/13) of Korean VHL
patients were classified as de novo patients. This de novo
mutation is probably due to sporadic germline VHL mu-
tations or can be inherited from a mosaic parent [4].
Sgambati et al. [8] reported 4.8 % rate of mosaicism in
asymptomatic parents of de novo VHL patients, a finding
that is similar to that reported in families affected with
Type 2 neurofibromatosis (NF2). Decker et al. [18] re-
ported that de novo mutations may have up to 20 % inci-
dence. Recently, a higher prevalence of de novo VHL
germline mutations (56.3 %) was reported in China [19].
Notably, we observed a significantly lower number of
VHL-related tumors in sporadic VHL patients than in
patients with a family history of VHL (Fig. 3a). This find-
ing reveals that the de novo VHL patients have mild phe-
notypes; the proband first affected in the family is most
likely to carry mosaic VHL mutations.
The high incidence of Glu70Lys mutation observed in
this study (frequency of 23.1 %) and its limited range of
manifestations (either CHB or RHB) corresponds well
with the findings of Hwang et al. [20]. While previous
VHL studies described codons 167, 76, 98, 65, and 78 as
frequently mutated regions, there are only a few reports
of Glu70Lys mutation in different ethnic groups [21, 22].
Mettu et al. [21] reported that among the 412 VHL pa-
tients studied, only one patient (frequency of 0.24 %)
carried the Glu70Lys mutation. Since this mutation is
highly frequent in Korean populations [20], codon 70
seems to be the hot spot region in the ethnic specific
mutational spectrum.
It has been reported that VHL type 2 is exclusively
correlated with missense mutations that cause changes
in the amino acids surface of the pVHL, and these pro-
teins retain its ability to downregulate HIF-α [4, 6, 18].
Interestingly, the results of the present study demon-
strate that PCC does not always occur in association
with a single amino acid change. The p.Leu198Trpfs*4
mutation was observed in 1 PCC patient. Since this
frameshift mutation is located in the 3′-most exon, it is
unable to cause a complete loss of pVHL function.
These findings are consistent with the hypothesis that
some retention of pVHL function is critical for tumori-
genesis in PCC [23].
Notably, we identified a novel frameshift mutation in
Korean VHL patients, c.160_161delAT (p.Met54-
Glyfs*77), which occurs in codon 54 and induces a pre-
mature stop at codon 130.
The major limitations of this study were the small
number of patients analyzed and the examination of
only one ethnic group, limiting the generalization of the
study results. However, our findings revealed that a mis-
sense mutation in the HIF-α binding site serves as a dis-
tinct predictor for early onset CHB. This study enhances
the efficacy of the surveillance of VHL patients.
Conclusions
The present study evaluated the genotype-specific phe-
notypes of VHL in the Korean population. The findings
in our study will provide insights for the genetic
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counseling and management of families suffering from
VHL. Missense mutations that disrupt HIF-α binding
may predispose to early-onset CHB in Korean VHL pa-
tients. It is recommended that patients carrying these
mutations undergo aggressive screening and early treat-
ment for CHB to achieve a better treatment outcome.
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